Abstract #1183049: Hypertension (HTN) and Diabetes (DM) Improvement During Osilodrostat Therapy in Patients with Cushing’s Disease (CD): Analyses from the Phase III LINC 3 study

Abstract

CD is a deleterious hypercortisolism disorder. Alleviating the burden of CD-associated comorbidities, including HTN and DM, is a key treatment goal. Osilodrostat, a potent oral 11β-hydroxylase inhibitor, normalized urinary free cortisol (UFC) and improved clinical signs and symptoms in CD patients (pts) in the Phase III LINC 3 study (NCT02180217). We describe blood pressure (BP) and glucose homeostasis changes in pts with baseline (BL) HTN and DM.